MedPath

Oncolytics Biotech Inc Anticipates Key Clinical Data Readouts in 2025

Oncolytics Biotech Inc is gearing up for a pivotal year in 2025, with expected data readouts from its clinical development program following the promising BRACELET-1 trial results. These developments are seen as crucial steps towards future commercialization opportunities in the pharmaceutical sector.

Oncolytics Biotech Inc's Clinical Milestones

Following a successful 2024, Oncolytics Biotech Inc is looking forward to a series of significant clinical data readouts in 2025. These anticipated results are part of the company's ongoing clinical development program, which has already shown promise with the BRACELET-1 trial.

BRACELET-1 Trial and Future Prospects

The BRACELET-1 trial has been a cornerstone in Oncolytics' research, providing encouraging results that have set the stage for the next phase of clinical trials. The company believes that the upcoming data readouts will not only validate their current research but also pave the way for future commercialization opportunities.

Market Response

Investors have shown optimism towards Oncolytics Biotech Inc's prospects, as evidenced by the slight uptick in the company's stock price. Shares of Oncolytics Biotech Inc (T.ONC) were trading up by $0.03 at $1.22, reflecting the market's positive reception to the company's clinical advancements and future outlook.
As Oncolytics Biotech Inc moves closer to these critical data readouts, the pharmaceutical and investment communities are keenly watching. The outcomes of these trials could significantly impact the company's trajectory and its contributions to medical treatments in the oncology field.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Molecular Partners and Orano Med Expand Partnership for Cancer Therapy Development

Molecular Partners and Orano Med have announced an expanded partnership to develop Targeted Alpha Radio-Therapies for cancer, aiming to enter a first-in-human study for Radio-DARPin MP0712 against DLL3 by 2025 and co-develop a program targeting Mesothelin.

IO Biotech Faces Nasdaq Delisting Risk Despite Promising Cancer Vaccine Advances

IO Biotech received a Nasdaq warning for its stock price falling below $1.00 for 30 consecutive days, risking delisting.
The company has until June 2025 to regain compliance by maintaining a stock price above $1.00 for at least 10 days.

Gilead's Trodelvy Receives FDA Breakthrough Therapy Designation for SCLC; Seladelpar Recommended for EU Approval

The FDA granted Breakthrough Therapy Designation to Gilead's Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy, based on promising results from the TROPiCS-03 study.
Gilead will collaborate with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets, leveraging Terray's tNova platform.

ASX Biotech Shares Surge on Cancer Trial Progress, Diagnostic Milestones

Race Oncology's stock jumped following the submission of a human ethics application for its RC220 Phase 1 solid tumour trial, with patient recruitment expected in Q1 2025.
Inoviq Ltd. reported successful disease specificity testing for its neuCA15-3 blood test, showing high sensitivity and specificity in detecting breast cancer across all stages.

Intensity Therapeutics Secures $3 Million to Advance Cancer Therapies

Intensity Therapeutics has secured $3 million through a direct stock offering and private placement to bolster its working capital.
The funds will support ongoing clinical trials, including a Phase 3 trial for soft tissue sarcoma and a Phase 2/3 program for triple-negative breast cancer.

Oncolytics Biotech's Pelareorep Shows Promising Survival Benefit in Breast Cancer

BRACELET-1 trial data reveals a significant overall survival benefit with pelareorep plus paclitaxel in HR+/HER2- metastatic breast cancer, supporting further registrational study.
Oncolytics Biotech anticipates updated efficacy data from the GOBLET study's anal cancer cohort and safety data from the modified FOLFIRINOX pancreatic cancer cohort in H1 2025.

Roche to Acquire Poseida Therapeutics; Merck, AstraZeneca, and Novartis Report Pipeline Success

Roche will acquire Poseida Therapeutics for $1.0 billion, expanding its CAR-T therapy portfolio, targeting hematological malignancies, solid tumors, and autoimmune diseases.
Merck's Winrevair phase III study met its primary endpoint, showing a statistically significant reduction in morbidity or mortality events in advanced pulmonary arterial hypertension.

Biofrontera's Ameluz Demonstrates Success in Phase III sBCC Trial, Stock Surges

Biofrontera's Ameluz-PDT therapy met the primary endpoint in a Phase III trial for superficial basal cell carcinoma (sBCC), showing significant clinical and histological clearance.
The Ameluz-PDT treatment achieved a 65.5% success rate compared to 4.8% in the placebo group, marking a substantial improvement in sBCC lesion clearance.

COGT Stock Hits 52-Week High at $12.2 Amid Market Optimism

Cogent Biosciences Inc. (COGT) shares reached a 52-week high of $12.2, reflecting strong investor confidence and significant progress in clinical trials for its KIT inhibitor drug, bezuclastinib. Analysts have updated their price targets and ratings based on the company's advancements and the broader growth in the biotechnology sector.

Oncolytics Biotech Pursues Accelerated Approval for Pelareorep in Breast and Pancreatic Cancers

Oncolytics Biotech plans to submit a pelareorep and paclitaxel combination therapy trial to the FDA in early 2025 for HR+/HER2- metastatic breast cancer, seeking accelerated approval.
The planned Phase 2 study will enroll approximately 180 patients who have progressed on or are ineligible for antibody-drug conjugates (ADCs), addressing a significant unmet need.

Reference News

[1]
Stocks in play: Oncolytics Biotech Inc
ca.finance.yahoo.com · Dec 23, 2024

Oncolytics Biotech Inc anticipates 2025 data readouts from its clinical program, following BRACELET-1 success, aiming fo...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy